Ad Watchdog Flags Nucleus Genomics IVF Embryo Screening Claims
NAD says Nucleus Genomics must modify or drop claims its IVF+ service can predict embryo traits like height, intelligence, and eye color.
A national advertising watchdog is pushing back against bold marketing claims made by a genetic testing startup. BBB National Programs' National Advertising Division (NAD) has recommended that Nucleus Genomics, Inc. modify or discontinue several express and implied advertising claims for its Nucleus IVF+ embryo screening service, following a monitoring inquiry into the company's promotional materials.
At the center of the dispute are assertions that Nucleus IVF+ can accurately compare embryos' disease risks, identify which embryo would grow up tallest or smartest, and even predict a future child's eye and hair colors. The NAD determined these claims required modification or removal, signaling concern that the marketing overstates what current genomic science can reliably deliver to prospective parents undergoing IVF.
Read more Budget Smartphones Under $100 Disappearing as AI Drives Up Memory Costs →
The ruling carries significant weight in the rapidly growing field of preimplantation genetic testing, where companies are racing to offer consumers increasingly detailed embryo profiles. Critics of such services have long argued that complex polygenic traits — like intelligence or height — cannot be meaningfully predicted from embryo DNA alone, and that marketing suggesting otherwise risks misleading vulnerable families navigating fertility treatment.
Nucleus Genomics has indicated it will appeal the NAD's decision, meaning the case is not yet closed. Appeals within the NAD process allow companies to challenge findings before a separate appellate body, potentially preserving their advertising in its current form while the review proceeds. The outcome could set a meaningful precedent for how genetic screening companies are permitted to market predictive embryo traits to consumers.
Continue reading at GlobalNewswire.
